Journal Menu
Submit Manuscript via ScholarOne

Eurasian Journal of Analytical Chemistry
Volume 12, Issue 2 (March 2017), pp. 31-44

DOI: 10.12973/ejac.2017.00152a

Downloaded 3122 times.

Research Article

Published online on Dec 08, 2016

How to reference this article?

 

A New Stability-Indicating and Validated RP-HPLC Method for the Estimation of Liraglutide in Bulk and Pharmaceutical Dosage Forms

Jhansi Naga Lakshmi Pedaprolu, Mohan Gandhi Bonthu, Bhaskara Raju Vatchavai, Srinivas Sumanth Kamatham, Srinivas Kolli, & Andal Naga Jyothi Kapuganti

Abstract

A stability-indicating RP-HPLC method was developed and validated for the estimation of Liraglutide in bulk and pharmaceutical dosage forms. Shiseido C18 (250 mm x 4.6 mm I.D., 5 µm particle size) column was used as stationary phase with mobile phase consisting methanol+acetonitrile (80:20): phosphate buffer (pH 3.0 adjusted with ortho phosphoric acid) in the ratio of 75:25, v/v. The flow rate was maintained at 1.2 ml/min and effluents were monitored at 245 nm. The retention time was found to be 2.837 minutes. The forced degradation studies were performed as per ICH guidelines under acidic, alkali, oxidative, thermal, photostability and neutral conditions. The drug peak was well resolved from the peaks of degraded products. From the degradation studies it is evident that the drug showed instability under acidic, alkali, oxidative, thermal, photostability and neutral conditions. The linearity of the method was observed in the concentration range of 10-60 µg/ml with the number of theoretical plates & tailing factor being 5550 & 1.17 respectively with a correlation coefficient of 0.999. The percentage assay of Liraglutide was found to be 99.66%. The method was validated for its accuracy, precision and system suitability. The results obtained in the study were within the limits of ICH guidelines and hence this method can be used for the estimation of Liraglutide in bulk and pharmaceutical dosage forms. 

Keywords: liraglutide, RP-HPLC, forced degradation, validation


References
  1. Liraglutide. (2015, April 03). Retrieved February 01, 2016, from http://www.medicinenet.com/liraglutide/article.htm
  2. Liraglutide Injection. (2015, August 15). Retrieved February 15, 2016, from https://www.nlm.nih.gov/medlineplus/druginfo/meds/a611003.html
  3. Liraglutide. (2016, May 30). Retrieved June 16, 2016, from https://www.drugs.com/cdi/liraglutide.html
  4. Victoza, Liraglutide (rDNA) injection. (2016, March 01). Retrieved June 16, 2016, from https://www.victoza.com/
  5. Victoza. (2015, March 13). Retrieved January 01, 2016, from http://www.rxlist.com/victoza-drug.htm
  6. Satyanarayana, P. V. V., & Madhavi, A. S. (2012). Validated RP-HPLC Method for Estimation of Liraglutide in Tablet Dosage Form. International Journal of Science Inventions today, 1, 1-17.
  7. Susena, S., Vanitha Praksh, K., Radika, T., Tejaswini, R., & Manasa, E. (2013). A Novel validated RP-HPLC method for the estimation of Liraglutide in bulk and Parenteral Dosage form. American Journal of PharmTech Research, 3, 807-813.
  8. ICH Harmonised Tripartite Guideline. (2005). Validation of analytical procedures: Text and methodology, Q2 (R1). International Conference on Harmonization, 1-13. 
  9. ICH Harmonised Tripartite Guideline. (2003). Stability Testing of New Drug Substances and Products, Q1A (R2). International Conference on Harmonization, 1-18.